Potential impact of optimal implementation of evidence-based heart failure therapies on mortality.

[1]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[2]  J. Healey,et al.  Cardiac-resynchronization therapy for mild-to-moderate heart failure. , 2010, The New England journal of medicine.

[3]  G. Fonarow,et al.  Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology Practices: Primary Results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) , 2010, Circulation.

[4]  J. Spertus,et al.  Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program. , 2010, Journal of the American College of Cardiology.

[5]  G. Fonarow,et al.  Relationships between emerging measures of heart failure processes of care and clinical outcomes. , 2010, American heart journal.

[6]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.

[7]  C. O'connor,et al.  Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure , 2010, Circulation. Heart failure.

[8]  C. Yancy,et al.  Use of aldosterone antagonists in heart failure. , 2009, Journal of the American Medical Association (JAMA).

[9]  D. Liew,et al.  Potential survival gains in the treatment of myocardial infarction , 2009, Heart.

[10]  G. Fonarow,et al.  Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. , 2009, Journal of the American College of Cardiology.

[11]  J. Spertus,et al.  Impact of Age and Medical Comorbidity on the Effectiveness of Implantable Cardioverter-Defibrillators for Primary Prevention , 2009, Circulation. Cardiovascular quality and outcomes.

[12]  F. McAlister,et al.  Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. , 2008, European heart journal.

[13]  Kevin L. Thomas,et al.  Use of Cardiac Resynchronization Therapy in Patients Hospitalized With Heart Failure , 2008, Circulation.

[14]  C. O'connor,et al.  Heart Failure Care in the Outpatient Cardiology Practice Setting: Findings From IMPROVE HF , 2008, Circulation. Heart failure.

[15]  P. Groeneveld,et al.  Outcomes and costs of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death among the elderly. , 2008, Heart rhythm.

[16]  B. Vandermeer,et al.  Systematic Review: Implantable Cardioverter Defibrillators for Adults with Left Ventricular Systolic Dysfunction , 2007, Annals of Internal Medicine.

[17]  Nancy M Albert,et al.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.

[18]  Ben Vandermeer,et al.  Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. , 2007, JAMA.

[19]  Eric Boersma,et al.  Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. , 2006, European heart journal.

[20]  D. Angus,et al.  Cost-Effectiveness of Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine Therapy for Blacks With Heart Failure , 2005, Circulation.

[21]  Douglas K Owens,et al.  Cost-effectiveness of implantable cardioverter-defibrillators. , 2005, The New England journal of medicine.

[22]  E. Antman,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[23]  A. Laupacis,et al.  Risk-treatment mismatch in the pharmacotherapy of heart failure. , 2005, JAMA.

[24]  S. Gottlieb,et al.  The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. , 2005, Journal of the American College of Cardiology.

[25]  C. Yancy,et al.  Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry. , 2005, Archives of internal medicine.

[26]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[27]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[28]  Akshay S. Desai,et al.  Implantable Defibrillators for the Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-analysis of Randomized Controlled Trials , 2004 .

[29]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[30]  J. McMurray,et al.  Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. , 2004, Journal of the American College of Cardiology.

[31]  H. Krumholz,et al.  National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction , 2004, Circulation.

[32]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, New England Journal of Medicine.

[33]  B. Pitt,et al.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. , 2003, The New England journal of medicine.

[34]  D. Clair,et al.  Brave New Brain: Conquering Mental Illness in the Era of the Genome , 2002, Heredity.

[35]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[36]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[37]  M. Konstam,et al.  Economic impact of beta blockade in heart failure. , 2001, The American journal of medicine.

[38]  J. Rouleau,et al.  β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis , 2001 .

[39]  W. Mcghan,et al.  Preferences for treatment outcomes in patients with heart failure: symptoms versus survival. , 2000, Journal of cardiac failure.

[40]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[41]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[42]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[43]  R. Califf,et al.  Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial. , 1998, Journal of the American College of Cardiology.

[44]  P. Heidenreich,et al.  Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. , 1997, Journal of the American College of Cardiology.

[45]  B. Kinosian,et al.  Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. , 1995, Journal of cardiac failure.

[46]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[47]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[48]  D. Mozaffarian,et al.  Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.

[49]  H. Glick,et al.  Economic Evaluation of the Randomized Aldactone Evaluation Study (RALES): Treatment of Patients with Severe Heart Failure , 2004, Cardiovascular Drugs and Therapy.